Kyntra Bio filings document the company's public-company governance, financial reporting, clinical-development updates, and Nasdaq listing matters. Recent 8-K reports cover results of operations and financial condition, including business updates tied to FG-3246, roxadustat, and the FG-3180 biomarker program.
The filing record also includes definitive proxy statements that disclose governance matters, executive compensation, equity awards, and shareholder voting information. Additional 8-K disclosure addresses Nasdaq continued-listing compliance, reflecting the company's capital-market and reporting obligations as a Nasdaq-listed biopharmaceutical issuer.
Kyntra Bio, Inc. (KYNB) director Andrew E. Singer was granted 14,000 stock options on October 1, 2026, covering 14,000 shares of common stock. The options have a $6.50 per-share exercise price, vest in twelve equal quarterly installments measured from the grant date, and expire September 30, 2036.
Andrew E. Singer is identified as a director of Kyntra Bio, Inc. in an initial ownership report.
Kyntra Bio, Inc. received a Nasdaq staff determination to delist its common stock after the company had not yet demonstrated compliance with a continued-listing requirement as of September 29, 2026. Kyntra Bio requested a hearing to seek additional time to regain compliance. The request stays the suspension of its securities and the filing of a Form 25-NSE pending the Nasdaq Hearings Panel’s written decision. The stock remains listed and trading on the Nasdaq Global Select Market while the Panel reviews the determination; an extension could be up to 180 days.
Kyntra Bio had previously disclosed that it did not meet Nasdaq’s total-asset and total-revenue standard or the alternative stockholders’ equity or market-value standards. The company is preparing a compliance plan, but said there can be no assurance the Panel will grant additional time or that it will regain compliance during any extension.
Kyntra Bio (KYNB) appointed Andrew E. Singer, MBA, as a Class III director and Audit Committee member, effective October 1, 2026; his board term expires in 2029. Maykin Ho, Ph.D., resigned from the board effective September 30, 2026. The company said her resignation was not the result of a disagreement with the company or its management.
On September 30, 2026, Kyntra Bio entered a new Change in Control and Severance Agreement with CEO Thane Wettig, replacing his prior agreement. The new agreement has a three-year term through October 2, 2029, and the company reported no material changes to the compensation or benefits payable under it.
KYNTRA BIO, INC. (KYNB) reported that CEO and director Thane Wettig26,796 shares directly and 40 shares indirectly through his spouse. No transactions were reported under a Rule 10b5-1 trading plan.
KYNTRA BIO, INC. (KYNB) reported that Chief Financial Officer David DeLucia had 22 shares of common stock disposed of on September 6, 2026 as part of a tax-withholding disposition related to vesting restricted stock units. The shares were withheld by the issuer to satisfy a tax obligation, not sold in an open-market trade. Following this event, DeLucia holds 4,355 shares of KYNTRA BIO common stock directly, and no Rule 10b5-1 trading plan is reported for this transaction.
Kyntra Bio, Inc. (KYNB) amended and restated its Revenue Interest Financing Agreement with NQ Project Phoebus, L.P., cutting the maximum aggregate payments from $125 million to $65 million. This materially reduces royalty-financing obligations by $60 million and eliminates all future true-up payments.
In exchange, Kyntra Bio made a $42.6 million accelerated upfront payment, bringing total payments to NQ Project Phoebus to $50 million, a full return of invested capital. Remaining payments are capped at $15 million, funded by 50% of roxadustat revenue received from Astellas in territories excluding Japan; after that cap, Kyntra Bio retains all subsequent EVRENZO royalties in those territories, and Japan royalties are already unrestricted.
The company also reports that the FibroGen Europe bankruptcy and settlement of related obligations have, together with the amended royalty agreement, reduced future liabilities by approximately $80 million. Cash, cash equivalents, investments, and accounts receivable were $95.7 million as of June 30, 2026, or $53.1 million pro forma for the upfront payment, with a cash runway expected into the fourth quarter of 2027.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of Kyntra Bio, Inc. common stock. They report beneficial ownership of 400,000 shares of common stock, representing 9.88% of the class. All reported shares are subject to shared voting and shared dispositive power; neither reporting person has sole voting or dispositive power.
Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises voting and investment power over these securities under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, may be deemed to beneficially own the same securities. The Master Fund is entitled to receive dividends and sale proceeds on the reported securities, while it specifically disclaims beneficial ownership because it cannot vote or dispose of the shares under the Investment Management Agreement.
Kyntra Bio, Inc. reported results for the quarter ended June 30, 2026, highlighted by a non‑cash $30.9 million gain from the deconsolidation of its bankrupt European subsidiary, FibroGen Europe. This produced income from continuing operations of $12.0 million (basic and diluted EPS $2.96), compared with a $13.7 million loss a year earlier, despite an operating loss of $17.6 million.
Total revenue from continuing operations was $(1.5) million for the quarter and $2.3 million for the first half, driven mainly by drug product sales and variable‑consideration true‑ups under Astellas agreements. Operating costs rose to $16.1 million in the quarter and $33.7 million year‑to‑date, reflecting higher legal expenses, Phase 2 FG‑3246 trial spending and product costs, partially offset by lower headcount, facilities and stock‑based compensation.
For the first six months, loss from continuing operations narrowed to $3.2 million from $30.4 million a year earlier, but operating activities used $17.9 million of cash versus $15.4 million provided in the prior period. Cash, cash equivalents, short‑ and long‑term investments and accounts receivable totaled about $95.7 million at June 30, 2026. Management states this liquidity is expected to fund planned operations for at least 12 months. The company remains focused on its FG‑3246 ADC program in mCRPC and preparing a Phase 3 program for oral roxadustat in lower‑risk MDS.
Kyntra Bio, Inc. reported second quarter 2026 results showing a sharp swing to profitability driven by a one‑time gain while core revenue declined. Total revenue from continuing operations was $(1.5) million for the quarter, compared with $1.3 million a year earlier, reflecting negative drug product revenue. Net income from continuing operations was $12.0 million, or $2.96 per basic and diluted share, versus a net loss of $13.7 million, or $(3.38) per share, primarily due to a $30.9 million gain on deconsolidation of a subsidiary. As of June 30, 2026, cash, cash equivalents, investments, and accounts receivable totaled $95.7 million, and the company expects this to fund operating plans into 2028.
Operationally, enrollment continues in the Phase 2 monotherapy trial of FG‑3246, an antibody‑drug conjugate targeting CD46 in metastatic castration‑resistant prostate cancer, with an interim analysis planned for the fourth quarter of 2026. The pivotal Phase 3 protocol for roxadustat in anemia related to lower‑risk myelodysplastic syndromes with high transfusion burden has been finalized, with a goal to initiate the registrational study in the fourth quarter of 2026. Additional Phase 3 MATTERHORN data presented at the European Hematology Association Congress 2026 highlighted improvements in transfusion independence for high transfusion burden patients treated with roxadustat.